Activating mutations in the epidermal growth factor receptor (EGFR) are key drivers of non-small-cell lung cancer (NSCLC) in 10–15% of Caucasian patients and 50% of Asian patients [1,2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.